Elizabeth Anderson
LeapRate Analyst

With over a decade’s experience as a finance writer, Elizabeth Anderson applies her knowledge and experience to keep a finger on the pulse of global trends. Specialising in forex, cryptocurrencies, and stocks, Elizabeth follows the movements that impact the world of trading.
May 02, 2024 BY Elizabeth Anderson

ASIC Issues Warning About New Scam Targeting Bonds And Term Deposits

These fraudsters reportedly zoom in on providers with no digital footprint. According to ASIC, they clone the disclosures, addresses, International Securities Identification Numbers (ISINs) and other official registration information of a targeted financial company. ASIC further indicated that the scams involve mirrored investment maturity dates, coupons and credit ratings. Apart from lesser-known organisations, these confidence…

Read more
SEC building
May 01, 2024 BY Elizabeth Anderson

Legal Clash Between SEC And Ripple Impacts XRP Performance

The virtual token regained some ground on Monday, 29 April 2024, after a loss of 1.51% on the previous day. Ripple filed a motion to strike the testimony of SEC accountant Andrea Fox. The regulator opposed this motion and categorised Fox as a summary witness. The objection read: Ripple incorrectly claims this declaration constitutes undisclosed…

Read more
European Central Bank
May 01, 2024 BY Elizabeth Anderson

Eurozone Exits Recession Thanks To Chief Economies

Eurostat, the EU’s statistical arm, reported a 0.3% quarter-over-quarter increase in both the euro area and the EU. During Q4 2023, GDP reflected a 0.1% decrease. Analysts attributed this positive uptick to expedited growth in the four chief economies in the Eurozone. Year on year, consumer prices increased by 2.4% in April 2024, mirroring the…

Read more
Getir delivery bike
April 30, 2024 BY Elizabeth Anderson

Getir Exits Europe And US To Concentrate On Local Market

Compared with the company’s recent expansion, this move seems like a sudden and contradictory shift. Getir’s business spiked during the pandemic years and caught the attention of prominent investors. According to Reuters, the company was valued at roughly $12bn approximately two years ago. Following its success, Getir expanded its footprint in Western Europe and New…

Read more
AUD USD
April 29, 2024 BY Elizabeth Anderson

AUD Looks To End April On A Positive Note

At the time of reporting, the currency has retained its strong footing and, in the European session, traded 0.24% up against the US dollar (USD) at 0.6534. Economists attributed this robust performance to the country’s Q1 Producer Price Index (PPI) data, which reflected a year-on-year growth of 4.3% and outstripped the predicted 2.6%. PPI for…

Read more
Paramount
April 29, 2024 BY Elizabeth Anderson

No Curtain Call For Paramount’s CEO As Skydance Merger Looms

According to CNBC, those close to the matter indicated that Bakish would not be attending the company’s quarterly earnings call scheduled for Monday. Instead, the international media and entertainment giant will rely on its segment heads to handle the event. The firm is currently in talks with Skydance Media, a private outfit, about a possible…

Read more
April 26, 2024 BY Elizabeth Anderson

Gold Price Holds Steady While US GDP Shakes Up Dollar

The US Bureau of Economic Analysis (BEA) said that during Q1 2024, US GDP grew by 1.6% according to the ‘advance’ estimate. The BEA stated: In the fourth quarter of 2023, real GDP increased 3.4 percent. The increase in the first quarter primarily reflected increases in consumer spending and housing investment that were partly offset…

Read more
Stellantis sign
April 26, 2024 BY Elizabeth Anderson

Stellantis Says Limiting Petrol Car Sales Will Hurt UK Economy

The Telegraph reported that the clampdown on the sale and ownership of combustion engines may force Stellantis to cease operations in Britain. According to the Telegraph, Carlos Tavares, the chief executive officer of Stellantis, indicated that a law curbing petrol car sales will compel manufacturers to either sell vehicles at a loss, limit the amount…

Read more
Biogen building
April 25, 2024 BY Elizabeth Anderson

Biogen Reaps Profits On The Back Of Cost Cuts

Economists attributed this positive performance to the biotechnological company’s cost-cutting drive and an uptake in sales of its newly-launched Alzheimer’s drug, LEQEMBI. Analysts predicted that the sales of this treatment would be between $13mn and $30mn. Biogen’s Q1 sales of LEQEMBI, as noted by its Japanese partner, Eisai Co., Ltd. (4523.T), were $19mn. Don’t miss…

Read more